- Home
- NUWE vs VIVS Comparison
NUWE vs VIVS Comparison
Compare NUWE & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUWE
- VIVS
- Stock Information
- Founded
- NUWE 1999
- VIVS 2007
- Country
- NUWE United States
- VIVS United States
- Employees
- NUWE N/A
- VIVS N/A
- Industry
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NUWE Health Care
- VIVS Health Care
- Exchange
- NUWE Nasdaq
- VIVS Nasdaq
- Market Cap
- NUWE 3.9M
- VIVS 4.2M
- IPO Year
- NUWE N/A
- VIVS N/A
- Fundamental
- Price
- NUWE $6.88
- VIVS $1.94
- Analyst Decision
- NUWE Strong Buy
- VIVS
- Analyst Count
- NUWE 1
- VIVS 0
- Target Price
- NUWE $714.00
- VIVS N/A
- AVG Volume (30 Days)
- NUWE 121.9K
- VIVS 59.1K
- Earning Date
- NUWE 08-12-2025
- VIVS 07-18-2025
- Dividend Yield
- NUWE N/A
- VIVS N/A
- EPS Growth
- NUWE N/A
- VIVS N/A
- EPS
- NUWE N/A
- VIVS N/A
- Revenue
- NUWE $8,787,000.00
- VIVS $144,000.00
- Revenue This Year
- NUWE $6.53
- VIVS $42.38
- Revenue Next Year
- NUWE $51.63
- VIVS $15.42
- P/E Ratio
- NUWE N/A
- VIVS N/A
- Revenue Growth
- NUWE N/A
- VIVS 32.11
- 52 Week Low
- NUWE $6.73
- VIVS $1.41
- 52 Week High
- NUWE $197.40
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- NUWE 25.34
- VIVS N/A
- Support Level
- NUWE $7.20
- VIVS N/A
- Resistance Level
- NUWE $10.08
- VIVS N/A
- Average True Range (ATR)
- NUWE 0.99
- VIVS 0.00
- MACD
- NUWE 0.64
- VIVS 0.00
- Stochastic Oscillator
- NUWE 10.66
- VIVS 0.00
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.